Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

28.21 -1.23 (-4.18%)
Streaming Delayed Price Updated: 11:32 AM EDT, Apr 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
While growth is established for NASDAQ:CPRX, the stock's valuation remains reasonable. ↗
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
Unlocking the Growth Potential of NASDAQ:CPRX. ↗
Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s CANSLIM characteristics. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why NASDAQ:CPRX qualifies as a high growth stock. ↗
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. 
Via Chartmill
News headline image
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout. ↗
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
News headline image
Unlocking the high Growth Potential of NASDAQ:CPRX. ↗
Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s high Growth Prospects. 
Via Chartmill
News headline image
BeiGene Stock Meets 80-Plus RS Rating Benchmark ↗
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday. 
Via Investor's Business Daily
News headline image
NASDAQ:CPRX, an undervalued stock with good fundamentals. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
BridgeBio Pharma Stock Earns 87 RS Rating ↗
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87. 
Via Investor's Business Daily
News headline image
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86 ↗
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical ↗
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing. 
Via Benzinga
Topics Intellectual Property
News headline image
NASDAQ:CPRX, a growth stock which is not overvalued. ↗
NASDAQ:CPRX is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. ↗
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
Should you consider NASDAQ:CPRX for growth investing? ↗
Exploring growth characteristics of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva ↗
One of Catalyst's key products has protection against a knockoff from Teva until 2035. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Arcellx Stock Earns 82 Relative Strength Rating ↗
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82. 
Via Investor's Business Daily
News headline image
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. ↗
Why the high growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
Unlocking the Growth Potential of NASDAQ:CPRX. ↗
Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s growth characteristics. 
Via Chartmill
News headline image
Why NASDAQ:CPRX qualifies as a high growth stock. ↗
Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for high growth investing? 
Via Chartmill
News headline image
Is NASDAQ:CPRX on the Verge of a Major Breakout as a Strong Growth Stock? ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
Neurocrine Biosciences Stock Sees RS Rating Upgrade ↗
Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71. 
Via Investor's Business Daily
News headline image
For those who appreciate value investing, NASDAQ:CPRX is a compelling option with its solid fundamentals. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating ↗
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95. 
Via Investor's Business Daily
News headline image
Don't overlook NASDAQ:CPRX—a stock with solid growth prospects and a reasonable valuation. ↗
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
Despite its impressive fundamentals, NASDAQ:CPRX remains undervalued. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), an undervalued stock with good fundamentals. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.